Search
Cabozantinib Action Pathway
smpdb.ca/view/SMP0126903Drug actionCabozantinib's mechanism of action involves inhibiting various receptor tyrosine kinases, effectively suppressing processes such as metastasis, angiogenesis, and oncogenesis, making it a versatile therapeutic
Enzymes: Coagulation factor XNintedanib Action Pathway
smpdb.ca/view/SMP0126909Drug actionIt's indicated for idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease, and chronic fibrosing interstitial lung diseases with a progressive phenotype, where it
Enzymes: Coagulation factor XBrolucizumab Action Pathway
smpdb.ca/view/SMP0126913Drug actionIt functions as a vascular endothelial growth factor (VEGF) inhibitor, specifically targeting major VEGF-A isoforms (VEGF110, VEGF121, and VEGF165). … Patients should be informed about potential risks, including endophthalmitis, retinal detachment, and arterial thromboembolic events, associated with this medication.
Enzymes: Coagulation factor XParnaparin Action Pathway
smpdb.ca/view/SMP0126175Drug actionParnaparin is a low-weight molecular heparin (LWMH), an anticoagulant that acts on antithrombin III in order to inhibit coagulation. … It can have interactions with food, it best to avoid herbs and supplements with anticoagulant and antiplatelet activity such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba.
Drugs: CalciumEnzymes: Coagulation factor XEnoxaparin Prothrombin Anticoagulation Action Pathway
smpdb.ca/view/SMP0126448Drug actionIt has an immediate onset of action, it binds to antithrombin III, inhibiting factor Xa ceasing the conversion of prothrombin to thrombin. … Enoxaparin can interact with some herbs and supplements, avoid those with anticoagulant and antiplatelet activity such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba.
Enzymes: Coagulation factor XPegaptanib Action Pathway
smpdb.ca/view/SMP0126889Drug actionPegaptanib serves as a selective vascular endothelial growth factor (VEGF) antagonist, employed to address neovascular (wet) age-related macular degeneration. … This treatment approach is especially effective for patients with conditions like wet AMD, where VEGF-A levels are elevated and contribute to disease progression.
Enzymes: Coagulation factor XRamucirumab Action Pathway
smpdb.ca/view/SMP0126890Drug actionRamucirumab serves as an antineoplastic agent and direct antagonist of VEGFR2 (vascular endothelial growth factor receptor 2), counteracting the binding of natural VEGF ligands secreted by solid tumors … It is a human monoclonal antibody (IgG1) designed against VEGFR2, a transmembrane tyrosine kinase receptor expressed on endothelial cells.
Enzymes: Coagulation factor XPazopanib Action Pathway
smpdb.ca/view/SMP0126899Drug actionBy targeting vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-alpha, PDGFR-beta), and c-kit, which are integral to the angiogenesis pathway … , inhibited growth, and hypoxia in cancer cells.
Enzymes: Coagulation factor XLenvatinib Action Pathway
smpdb.ca/view/SMP0126908Drug actionLenvatinib also inhibits other RTKs, such as fibroblast growth factor receptors (FGFR1, 2, 3, and 4), the platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET, all of which play crucial … It primarily targets the kinase activities of vascular endothelial growth factor (VEGF) receptors, including VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
Enzymes: Coagulation factor XRipretinib Action Pathway
smpdb.ca/view/SMP0126912Drug actionRipretinib's mechanism of action involves inhibiting protein kinases, including both wild type and mutant forms of platelet-derived growth factor receptor A (PDGFRA) and KIT, which are implicated in the … This medication has been shown to inhibit other genes like PDGFRB, BRAF, VEGF, and TIE2 in laboratory studies.
Enzymes: Coagulation factor X